

ASX Announcement

Medibio Limited – 10 OCT 2016



Funding Update

Sydney, Australia – 10 September 2016: Medibio Limited (MEB or the Company) is pleased to provide the following update on funding.

R&D Refund of \$3,074,224

Medibio lodged its company Tax Return on 23 September 2016 and expects to receive its associated R&D refund tax offset within the next 14 days. This \$3,074,224 R&D refund will be paid in cash to Medibio. The R&D Tax Incentive refund relates to the Advanced and Overseas Finding that Medibio received which covers the R&D activities for the year ended June 30th 2016.

Early Exercise of Options brings in \$900,000

3 shareholders have committed to the early exercise of unlisted options. Total commitments for early exercise are \$900,000 of which \$400,000 in cleared funds has been received to date. The company would like to thank these shareholders for committing to an early exercise.

Additional Grant Funding potential of \$4 million

On 23 September 2016 Medibio lodged an Accelerating Commercialisation EOI for a \$1m grant to help fast-track the commercialisation of the company's diagnostic technology. Medibio also is currently finalising an application for a \$3m CRC-P grant. Medibio will update the market as these applications progress and expects to know the outcome of both applications by early 2017.

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036231	

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.